hotspot -WSS

hotspot

author：hotspot 2025-10-03 01:05:15 - browse：6475

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The Food and Drug Administration on Thursday approved an Eli Lilly drug that takes a new approach to treating ulcerative colitis, a chronic inflammatory disease that can cause intense gastrointestinal pain and distress.

The therapy, dubbed Omvoh, is an antibody that blocks IL-23p19, an immune signaling molecule that plays a key role in sustaining the disease. It’s the first treatment to target this particular pathway in ulcerative colitis. The drug’s approval comes after two late-stage trials found that patients taking Omvoh showed a significant improvement in symptoms after both three months and a year compared with those given a placebo, and that the therapy had minimal side effects.

Omvoh’s list price will be $9,593 per month for intravenous delivery and $10,360 per dose injected beneath the skin. A company spokesperson told STAT that patients who have the drug covered by commercial insurance may pay as little as $5 per month for up to 30 months.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Cord blood banking comes at a high cost to babies

explore

WSS

Stem cell clinics for heart failure: buyer be wary

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Letters to First Opinion on caregivers, digital health, and more

The Pandemic Treaty must support building strong health systems

The drug industry sees a key ally in the Senate prevail

A cyberattack has disrupted hospitals and health care in several states

hotspot

hotspot

leisure time

Heart attack and stroke risk calculators need revising

ER docs worry over extreme heat as a 'mass casualty event'

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The Pandemic Treaty must support building strong health systems

Psychedelics group wrestles with new pharma identity

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

Walensky prepares to leave CDC — and Congress — behind

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

Sports medicine is finally prioritizing gender equality

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Wikipedia

What Mike Pence has said that could be used in a Donald Trump trial

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Trump drops motion seeking removal of DA probing efforts to overturn 2020 election in Georgia

focus

leisure time

explore

Wikipedia